UNIVACFLU
Universal Flu Vaccine
| Coordinatore | GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
| Nazionalità Coordinatore | Sweden [SE] |
| Totale costo | 4˙116˙701 € |
| EC contributo | 4˙116˙701 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2013-ITN |
| Funding Scheme | MC-ITN |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-11-01 - 2017-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
GOETEBORGS UNIVERSITET
Organization address
address: VASAPARKEN contact info |
SE (GOETEBORG) | coordinator | 1˙159˙857.90 |
| 2 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 831˙765.44 |
| 3 |
VIB
Organization address
address: Rijvisschestraat 120 contact info |
BE (ZWIJNAARDE - GENT) | participant | 589˙160.00 |
| 4 |
MIVAC DEVELOPMENT AB
Organization address
address: ARVID WALLGRENS BACKE 20 contact info |
SE (GOTEBORG) | participant | 350˙966.88 |
| 5 |
UNIVERSITE DE LILLE II - DROIT ET SANTE
Organization address
address: RUE PAUL DUEZ 42 contact info |
FR (Lille) | participant | 345˙664.90 |
| 6 |
ISTITUTO EUROPEO DI ONCOLOGIA SRL
Organization address
address: Via Filodrammatici 10 contact info |
IT (MILANO) | participant | 325˙517.28 |
| 7 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | participant | 300˙491.84 |
| 8 |
RETROSCREEN VIROLOGY LTD
Organization address
address: NEW ROAD QUEEN MARY BIOENTERPRISE INNOVATION CENTRE 42 contact info |
UK (LONDON) | participant | 213˙276.80 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines. The aim is to establish a European training platform to integrate young researchers in a highly innovative interdisciplinary strategy to develop mucosal flu-vaccines. The Universal Influenza Vaccine (UNIFLUVAC) network is aimed at harnessing the expertise of the most accomplished vaccine researchers, developers and regulators in Europe in a timely and multidisciplinary training approach unparalleled in any single EU country. The training program is extensive and builds on the integrated added values of complementing expertise and the full access to state-of-the- art technologies and excellent training environments. This unique consortium has 2 SMEs as fully committed members to guarantee strong intersectoral cooperation between industry and academia.
The partners represent 6 leading universities in 6 different member countries, securing excellent presence in Europe. The structure of UNIFLUVAC is specifically adapted to operate over the whole range of specialized expertise needed. Specifically, UNIFLUVAC provides vaccine antigen identification and expression, adjuvant design and formulation, testing in state-of-the-art preclinical animal models and finally clinical safety, immunogenicity and efficacy trials in excellent and for Europe unique medical centres. This is the strength and appeal of the UNIFLUVAC proposal. It will also establish a long-term European network based on a new cohort of young professionals with excellent employability and career opportunities in academic, clinical or industrial settings. UNIFLUVAC will have a major impact on human health in Europe and globally.'